| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $160.9M | -25.4% |
| SG&A Expense | $50.4M | +0.7% |
| Operating Income | -$208.6M | +20.8% |
| Pre-tax Income | -$195.8M | +20.3% |
| Income Tax | $0 | -100.0% |
| Net Income | -$195.8M | +20.5% |
| EPS (Basic) | -$3.24 | +31.2% |
| EPS (Diluted) | -$3.24 | +31.2% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $26.5M | -76.5% |
| Current Assets | $193.6M | -44.3% |
| Total Assets | $265.7M | -37.2% |
| Current Liabilities | $37.6M | -11.4% |
| Total Liabilities | $217.5M | -1.2% |
| Stockholders' Equity | $48.2M | -76.3% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$153.0M | +20.4% |
| Capital Expenditures | $5.9M | -52.7% |
| Investing Cash Flow | $64.2M | -6.1% |
| Financing Cash Flow | $2.4M | -97.9% |
| Free Cash Flow | -$158.8M | +22.4% |